Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor

Yoonhwa Park, Sang Hyeok Woo, Sung Keum Seo, Hyunggee Kim, Woo Chul Noh, Jin Kyung Lee, Byoung Mog Kwon, Kyung Nam Min, Tae Boo Choe, In Chul Park

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ginkgetin is a natural biflavonoid isolated from the leaves of Ginkgo biloba, and is characterized by its anti-inflammatory and anti-viral activities. Although numerous studies state that it has also antitumor activity, the anti-proliferative effect of ginkgetin and the underlying mechanism in breast cancer cells have not yet been investigated. In the present study, ginkgetin inhibited the cell viability of MCF-7 and T-47D cells dose-dependently, and suppressed the expression of the estrogen receptor (ER) at the mRNA and protein levels. Among the targets of the ER, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), cyclin D1 and survivin were also downregulated by ginkgetin treatment. The anti-proliferative effects of ginkgetin were sufficient to suppress the growth by estradiol stimulation. However, ginkgetin did not significantly affect the viability of MDA-MB-231 cells, which are ER-negative cells. Furthermore, the knockdown of the ER and an inhibitor of PFKFB3 significantly sensitized MCF-7 and T-47D cells to ginkgetin. These findings suggest that ginkgetin induces cell death in ER-positive breast cancer cells via the inhibition of ER expression and that it is a promising agent for breast cancer treatment.

Original languageEnglish
Pages (from-to)5027-5033
Number of pages7
JournalOncology Letters
Volume14
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Estrogen Receptors
Cell Death
Down-Regulation
Breast Neoplasms
Phosphofructokinase-2
Biflavonoids
Ginkgo biloba
ginkgetin
Cyclin D1
Estradiol
Cell Survival
Anti-Inflammatory Agents
Messenger RNA
Growth
Proteins

Keywords

  • Apoptosis
  • Breast cancer
  • Estrogen receptor
  • Ginkgetin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Park, Y., Woo, S. H., Seo, S. K., Kim, H., Noh, W. C., Lee, J. K., ... Park, I. C. (2017). Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor. Oncology Letters, 14(4), 5027-5033. https://doi.org/10.3892/ol.2017.6742

Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor. / Park, Yoonhwa; Woo, Sang Hyeok; Seo, Sung Keum; Kim, Hyunggee; Noh, Woo Chul; Lee, Jin Kyung; Kwon, Byoung Mog; Min, Kyung Nam; Choe, Tae Boo; Park, In Chul.

In: Oncology Letters, Vol. 14, No. 4, 2017, p. 5027-5033.

Research output: Contribution to journalArticle

Park, Y, Woo, SH, Seo, SK, Kim, H, Noh, WC, Lee, JK, Kwon, BM, Min, KN, Choe, TB & Park, IC 2017, 'Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor', Oncology Letters, vol. 14, no. 4, pp. 5027-5033. https://doi.org/10.3892/ol.2017.6742
Park, Yoonhwa ; Woo, Sang Hyeok ; Seo, Sung Keum ; Kim, Hyunggee ; Noh, Woo Chul ; Lee, Jin Kyung ; Kwon, Byoung Mog ; Min, Kyung Nam ; Choe, Tae Boo ; Park, In Chul. / Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor. In: Oncology Letters. 2017 ; Vol. 14, No. 4. pp. 5027-5033.
@article{e0ed6d0b440c45e586f4eed81dd404a6,
title = "Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor",
abstract = "Ginkgetin is a natural biflavonoid isolated from the leaves of Ginkgo biloba, and is characterized by its anti-inflammatory and anti-viral activities. Although numerous studies state that it has also antitumor activity, the anti-proliferative effect of ginkgetin and the underlying mechanism in breast cancer cells have not yet been investigated. In the present study, ginkgetin inhibited the cell viability of MCF-7 and T-47D cells dose-dependently, and suppressed the expression of the estrogen receptor (ER) at the mRNA and protein levels. Among the targets of the ER, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), cyclin D1 and survivin were also downregulated by ginkgetin treatment. The anti-proliferative effects of ginkgetin were sufficient to suppress the growth by estradiol stimulation. However, ginkgetin did not significantly affect the viability of MDA-MB-231 cells, which are ER-negative cells. Furthermore, the knockdown of the ER and an inhibitor of PFKFB3 significantly sensitized MCF-7 and T-47D cells to ginkgetin. These findings suggest that ginkgetin induces cell death in ER-positive breast cancer cells via the inhibition of ER expression and that it is a promising agent for breast cancer treatment.",
keywords = "Apoptosis, Breast cancer, Estrogen receptor, Ginkgetin",
author = "Yoonhwa Park and Woo, {Sang Hyeok} and Seo, {Sung Keum} and Hyunggee Kim and Noh, {Woo Chul} and Lee, {Jin Kyung} and Kwon, {Byoung Mog} and Min, {Kyung Nam} and Choe, {Tae Boo} and Park, {In Chul}",
year = "2017",
doi = "10.3892/ol.2017.6742",
language = "English",
volume = "14",
pages = "5027--5033",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor

AU - Park, Yoonhwa

AU - Woo, Sang Hyeok

AU - Seo, Sung Keum

AU - Kim, Hyunggee

AU - Noh, Woo Chul

AU - Lee, Jin Kyung

AU - Kwon, Byoung Mog

AU - Min, Kyung Nam

AU - Choe, Tae Boo

AU - Park, In Chul

PY - 2017

Y1 - 2017

N2 - Ginkgetin is a natural biflavonoid isolated from the leaves of Ginkgo biloba, and is characterized by its anti-inflammatory and anti-viral activities. Although numerous studies state that it has also antitumor activity, the anti-proliferative effect of ginkgetin and the underlying mechanism in breast cancer cells have not yet been investigated. In the present study, ginkgetin inhibited the cell viability of MCF-7 and T-47D cells dose-dependently, and suppressed the expression of the estrogen receptor (ER) at the mRNA and protein levels. Among the targets of the ER, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), cyclin D1 and survivin were also downregulated by ginkgetin treatment. The anti-proliferative effects of ginkgetin were sufficient to suppress the growth by estradiol stimulation. However, ginkgetin did not significantly affect the viability of MDA-MB-231 cells, which are ER-negative cells. Furthermore, the knockdown of the ER and an inhibitor of PFKFB3 significantly sensitized MCF-7 and T-47D cells to ginkgetin. These findings suggest that ginkgetin induces cell death in ER-positive breast cancer cells via the inhibition of ER expression and that it is a promising agent for breast cancer treatment.

AB - Ginkgetin is a natural biflavonoid isolated from the leaves of Ginkgo biloba, and is characterized by its anti-inflammatory and anti-viral activities. Although numerous studies state that it has also antitumor activity, the anti-proliferative effect of ginkgetin and the underlying mechanism in breast cancer cells have not yet been investigated. In the present study, ginkgetin inhibited the cell viability of MCF-7 and T-47D cells dose-dependently, and suppressed the expression of the estrogen receptor (ER) at the mRNA and protein levels. Among the targets of the ER, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), cyclin D1 and survivin were also downregulated by ginkgetin treatment. The anti-proliferative effects of ginkgetin were sufficient to suppress the growth by estradiol stimulation. However, ginkgetin did not significantly affect the viability of MDA-MB-231 cells, which are ER-negative cells. Furthermore, the knockdown of the ER and an inhibitor of PFKFB3 significantly sensitized MCF-7 and T-47D cells to ginkgetin. These findings suggest that ginkgetin induces cell death in ER-positive breast cancer cells via the inhibition of ER expression and that it is a promising agent for breast cancer treatment.

KW - Apoptosis

KW - Breast cancer

KW - Estrogen receptor

KW - Ginkgetin

UR - http://www.scopus.com/inward/record.url?scp=85028924264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028924264&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.6742

DO - 10.3892/ol.2017.6742

M3 - Article

AN - SCOPUS:85028924264

VL - 14

SP - 5027

EP - 5033

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 4

ER -